ARK Investment Management LLC Sells 771,282 Shares of Twist Bioscience Co. (NASDAQ:TWST)

ARK Investment Management LLC cut its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 12.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,358,093 shares of the company’s stock after selling 771,282 shares during the period. Twist Bioscience comprises about 2.2% of ARK Investment Management LLC’s investment portfolio, making the stock its 13th biggest position. ARK Investment Management LLC owned approximately 0.09% of Twist Bioscience worth $242,079,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in TWST. Signaturefd LLC lifted its holdings in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new stake in shares of Twist Bioscience during the 2nd quarter valued at $43,000. Blue Trust Inc. lifted its stake in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience in the 2nd quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares in the last quarter.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $45.52 on Friday. The stock’s fifty day moving average is $43.65 and its 200 day moving average is $45.43. Twist Bioscience Co. has a fifty-two week low of $15.85 and a fifty-two week high of $60.90.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the sale, the chief executive officer now owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Dennis Cho sold 659 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $27,388.04. Following the transaction, the insider now owns 94,481 shares of the company’s stock, valued at $3,926,630.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 1,730 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the sale, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,656 shares of company stock valued at $1,791,419. 3.92% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Evercore ISI increased their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.